Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Lymphoma
Interventions: Drug: cyclophosphamide; Drug: prednisolone; Drug: vinblastine; Other: watchful waiting; Procedure: therapeutic conventional surgery
Sponsor: Martin-Luther-Universität Halle-Wittenberg
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Conditions: Hairy Cell Leukemia (HCL); Chronic Lymphocytic Leukemia (CLL); Non-Hodgkins Lymphoma (NHL); Cutaneous T Cell Lymphoma (CTCL); Adult T Cell Lymphoma (ATL)
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Conditions: Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma (DLBCL); Non-Hodgkin's Lymphoma (NHL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL)
Intervention: Drug: CAT-8015
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine
Sponsor: Calistoga Pharmaceuticals, Inc.
Not yet recruiting - verified March 2010
Conditions: Hodgkin's Disease; Non-Hodgkin Lymphomas; Multiple Myelomas
Intervention: Drug: lenograstim
Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; Ludwig-Maximilians - University of Munich; Chugai Pharma GmbH
Completed - verified March 2010
Condition: CNS Lymphoma
Intervention: Drug: MTX, MVD, VIA
Sponsor: Samsung Medical Center
Recruiting - verified March 2010
Condition: B Cell Malignancies
Intervention: Genetic: Anti-CD19-CAR-transduced T cells
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Condition: Acute Lymphoblastic Leukemia
Intervention:
Sponsor: National Taiwan University Hospital
Not yet recruiting - verified March 2010
Condition: Autoimmune Disease
Intervention: Drug: Rituximab
Sponsor: National Eye Institute (NEI)
Recruiting - verified October 2009
Conditions: Cancer; Solid Tumors; Lymphoma; Malignancy
Intervention: Drug: AT-406
Sponsor: Ascenta Therapeutics
Recruiting - verified March 2010
Conditions: Non Hodgkin Lymphoma; Hodgkin Lymphoma
Intervention: Drug: treosulfan
Sponsor: Sheba Medical Center
Recruiting - verified March 2010
Conditions: Cancer Survivor; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Testicular Germ Cell Tumor
Interventions: Genetic: DNA analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Lymphoma
Interventions: Drug: lenalidomide; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: University of Chicago; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Conditions: Leukemia; Mucositis; Oral Complications
Interventions: Biological: epratuzumab; Biological: palifermin; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Radiation: total-body irradiation
Sponsor: University College London Hospitals
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Interventions: Biological: rituximab; Drug: alvocidib; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Conditions: Lymphoma, Follicular; Lymphoma, Non-Hodgkin
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsor: GlaxoSmithKline
Not yet recruiting - verified February 2010
Conditions: Lymphoma; Hodgkin Disease
Interventions: Procedure: tumor tissue aspiration; Procedure: phlebotomy
Sponsor: Stanford University
Recruiting - verified February 2010
Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia; De Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Disease, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: plerixafor; Biological: filgrastim; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified February 2010
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-Cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: everolimus; Drug: lenalidomide; Other: laboratory biomarker analysis; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: fluorescence in situ hybridization
Sponsor: Mayo Clinic
Not yet recruiting - verified February 2010
Condition: Non-Hodgkin Lymphomas
Intervention: Drug: Ofatumumab
Sponsor: Oncology Specialists, S.C.
Recruiting - verified February 2010
Conditions: Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: bendamustine and rituximab
Sponsor: Cephalon
Recruiting - verified February 2010
Conditions: Follicular Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: Temsirolimus, Rituximab, Bendamustin
Sponsors: Johannes Gutenberg University Mainz; Wyeth; Mundipharma K.K.
Recruiting - verified November 2009
Condition: Lymphoma
Intervention: Radiation: TSEBT
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Condition: Acute Lymphoblastic Leukemia
Intervention:
Sponsor: Samsung Medical Center
Recruiting - verified March 2010
Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified February 2010
Condition: Leukemia, Lymphocytic, Acute
Interventions: Procedure: bone marrow aspiration; Procedure: peripheral blood sampling
Sponsor: Stanford University
Completed - verified February 2010
All Categories ... Medical Conditions » ... Cancers » ... Lymphoma 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
